drugset / Trial / NCT03512353
A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
NaSingle-groupOpen-labelTreatment
Summary
The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.
Timeline
- Start
- 2018-07-05
- Primary completion
- 2020-01-16
- Completion
- 2020-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 70 mg/m2 | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |